<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620853</url>
  </required_header>
  <id_info>
    <org_study_id>ASI-ALK-F</org_study_id>
    <nct_id>NCT01620853</nct_id>
  </id_info>
  <brief_title>Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)</brief_title>
  <official_title>Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Spectral Imaging Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Spectral Imaging Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is the identification of chromosomal aberrations in non-small cell
      lung cancer (NSCLC) .

      The imaging system is intended for diagnostic use as an aid to the pathologist in the
      detection, counting and classifying ALK FISH stained lung samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ALK Break Apart FISH test detects chromosomal aberrations via fluorescence in situ
      hybridization (FISH) in formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer
      (NSCLC) tissue specimens. The FDA approved ALK kit is designed to detect rearrangements
      involving the ALK gene (2p23). Results from the ALK Kit are intended for use, in conjunction
      with and not in lieu of current standard diagnostic procedures, as an aid for the pathologist
      in the identification of patients eligible for treatment with XALKORIÂ® (crizotinib).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IVD study</measure>
    <time_frame>1 Day</time_frame>
  </primary_outcome>
  <enrollment type="Actual">1</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients having non-small cell lung cancer (NSCLC)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Well stained slides with bright FISH signals

        Exclusion Criteria:

          -  Very old slides that were already bleached
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scott &amp; White Hospital,</name>
      <address>
        <city>Temple,</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>ALK probe</keyword>
  <keyword>FISH</keyword>
  <keyword>Chromosomal aberrations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

